Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SLDB
SOLID BIOSCIENCES INC.
NASDAQ
$9.77
▼ DOWN 3.55% (-0.36)

KEY STATISTICS

Market Cap$961.85 M
52w High$11.45
52w Low$3.79
Dividend Yield—
Frequency—
P/E-5.20
Volume621.51K
Shares Out.98.45M

COMPANY

LEADERSHIP

Alexander G. Cumbo
CHIEF EXECUTIVE
Alexander G. Cumbo

COMPENSATION 2026

Salary$650,988
Stock Awards$2,318,275
Incentive Plan Pay$0
All Other Comp.$12,600
Total$5,223,442

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 26, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
121

PRICE TARGET

Target High$26.00
Target Low$16.00
Target Median$19.00
Target Consensus$20.00

UPCOMING EARNINGS

DateNov 2, 2026
DayMonday
Rev. Est.—
NOV
2
MON

SPLIT RECORD

DATETYPERATIO
2022-10-28Reverse1:15

PRICE

$9.77 ▼ DOWN 3.55% (−$0.36)
OVERLAYS
$9.70$9.80$9.90$10.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM9.77

About Solid Biosciences Inc.

https://www.solidbio.com ↗

Solid Biosciences develops gene therapies for Duchenne muscular dystrophy, including SGT-001 and SGT-003, and collaborates with Ultragenyx to advance innovative treatments.

INDUSTRY

Biotechnology

A PRODUCT SOLID BIOSCIENCES INC. IS KNOWN FOR

SGT-003
SGT-003

SGT-003 is Solid Biosciences' investigational gene therapy for Duchenne muscular dystrophy, currently in Phase 1/2 trials with promising results in muscle health biomarkers.

COMPETITORS

COMPETITOR
CAPR COMPARE
DYN COMPARE
PFE COMPARE
RGNX COMPARE
SRPT COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
93
LISTED HERE
17
RANKED BY POSITION SIZE
VTI
0.00% · 3.1M
XBI
0.23% · 2.8M
XSU.TO
0.02% · 2.0M
FESM
0.08% · 490.4K
DFAS
0.02% · 293.6K
SBIO
0.49% · 121.8K
LABU
0.16% · 100.1K
PRFZ
0.03% · 96.5K
AVSC
0.03% · 81.3K
XRSG.L
0.03% · 71.9K
BBC
0.85% · 43.9K
RSSL
0.03% · 37.4K
MNTL
0.57% · 8.6K
RFLR
0.07% · 7.3K
BIB
0.03% · 3.5K
PWS
0.05% · 1.2K
RESM
0.03% · 154

INSTITUTIONAL OWNERSHIP

SHARES OWNED
82.71%
HOLDERS
209
TOP 12 OF 209 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
12.0M sh · $120.24M
Perceptive Advisors LLC
11.9M sh · $85.73M
Bain Capital Life Sciences Investors, LLC
9.8M sh · $97.99M
Siren, L.L.C.
7.7M sh · $76.83M
Blackrock, Inc.
6.9M sh · $69.27M
Fmr LLC
6.9M sh · $68.69M
Vestal Point Capital, LP
5.8M sh · $32.8M
Armistice Capital, LLC
4.3M sh · $42.74M
State Street Corp
4.2M sh · $41.71M
Janus Henderson Group Plc
4.0M sh · $28.88M
Adage Capital Partners Gp, L.L.C.
4.0M sh · $24.68M
Rtw Investments, LP
3.9M sh · $38.89M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
SMITH IAN F
Purchase · 3.4K shares
2026-07-02
★
DIRECTOR
SMITH IAN F
Sale · 3.4K shares
2026-07-02
★
10 PERCENT OWNER
RA CAPITAL MANAGEMENT, L.P.
— · —
2026-06-22
★
10 PERCENT OWNER
RA CAPITAL MANAGEMENT, L.P.
— · 8.2M shares
2026-06-22

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OVERWEIGHT 3
OUTPERFORM 1
9 GRADES IN THE LAST 12 MONTHS
Truist Securities BUY HC Wainwright & Co. BUY Wedbush OUTPERFORM Piper Sandler OVERWEIGHT JP Morgan OVERWEIGHT Chardan Capital BUY Needham BUY Citigroup BUY

SECTORS PEERS

PEERPRICE
LBRX$47.73COMPARE
DSGN$15.11COMPARE
ANNX$4.97COMPARE
AURA$7.40COMPARE
AUTL$2.34COMPARE
BNTC$12.47COMPARE
RCKT$3.86COMPARE
NMRA$1.39COMPARE